Pharmaxis Ltd

BTC Health Limited (ASX:BTC) is pleased to announce its investee company, BioImpact Pty Ltd, has acquired exclusive distribution rights for specialty respiratory brands Bronchitol(R) and Aridol(R) from Pharmaxis (ASX:PXS) in Australia, New Zealand, Singapore, Malaysia, Hong Kong and South Korea (Bronchitol(R) only).

Boehringer Ingelheim and pharmaceutical research company Pharmaxis (ASX:PXS) (OTCMKTS:PXSLY) announce that Boehringer Ingelheim is initiating the Phase IIa study ROBIN. This marks the beginning of the clinical development program for BI 1467335 in a second indication targeting a severe diabetes complication. An already ongoing Phase II clinical study program is investigating the compound in NASH.

Boehringer Ingelheim and pharmaceutical company Pharmaxis (ASX:PXS) (OTCMKTS:PXSLY) announce that Boehringer Ingelheim has initiated a European and North American Phase IIa trial in NASH with BI 1467335 (formerly known as PXS-4728A), acquired from Pharmaxis in May 2015.

Australian and New Zealand biotech investors are set to hear from a top line up of speakers from ASX-listed life science companies, as well as several private firms and international businesses, in July, at the 11th Bioshares Biotech Summit.

Australian Market Report of February 8, 2011 includes: Robust Resources Limited (ASX:ROL) has intersected near-surface high grade gold, silver and sulphide mineralisation in East Indonesia; Pharmaxis Limited (ASX:PXS) received approval for marketing Bronchitol in Australia to treat cystic fibrosis; St George Mining Limited (ASX:SGQ) announced new gold targets in Western Australia; Jatoil Limited (ASX:JAT) signed a deal to acquire coal assets in Queensland.

Australian Market Report of December 13, 2010 includes: Altura Mining Limited (ASX:AJM) has received approval for the upcoming drill program at Pilgangoora Lithium Project in WA; Orion Metals Limited (ASX:ORM) has received highly encouraging gold results at Killi Killi Hills Gold-Rare Earth Element Project; Pharmaxis Limited (ASX:PXS) announces that Bronchitol is recommended for approval By Australian Advisory Committee; Tabcorp Holdings Limited (ASX:TAH) proposed A$625 million expansion of its casinos in Queensland.

Pharmaxis (ASX: PXS) is undertaking a public offering of ordinary shares in the form of American Depositary Shares in the United States.

Pharmaxis Ltd (ASX: PXS) announced today the pricing of an underwritten public offering of 1,300,000 American Depositary Shares at a price of USD$24.16 per ADS. Each ADS represents 15 ordinary shares in Pharmaxis. CIBC World Markets Corp. acted as sole book-running manager of the offering.